You’re not imagining it: An unusually large number of Americans are barfing these days. Ninety-one norovirus outbreaks were ...

Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats ...

Earlier this month, Moderna announced business updates and progress across its pipeline. Moderna says it enters 2025 with a ...

Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu.

The latest funding is a sign of how seriously the Biden administration appears to be taking the pandemic threat.

In 2023, Moderna initiated a study on a “pandemic influenza vaccine” to protect against H5 and H7 avian influenza viruses. In July, the company received $176 million from HHS toward its ...

There have been 67 confirmed human bird flu cases in the U.S. since April 2024. Moderna has been awarded approximately $590 million from the federal government to help speed up the development of ...

Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial ...

Shares of Moderna Inc. rose over 5% on Tuesday morning, reaching levels last seen more than a week ago, following news of a ...

Moderna Inc. shares plunged after the company slashed its sales forecast for this year as it struggles with slow demand for its Covid and RSV vaccines. The Cambridge, Massachusetts-based company ...

Earlier this month, Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s lackluster vaccine sales in COVID-19 and respiratory ...